Glaukos Co. (NYSE:GKOS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in shares of Glaukos Co. (NYSE:GKOS) by 1.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 650,697 shares of the medical instruments supplier’s stock after purchasing an additional 8,936 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Glaukos were worth $97,566,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. WCM Investment Management LLC raised its holdings in shares of Glaukos by 45.7% during the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock worth $12,721,000 after acquiring an additional 31,084 shares during the period. BNP Paribas Financial Markets raised its holdings in Glaukos by 186.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after buying an additional 8,942 shares during the period. First Turn Management LLC purchased a new stake in Glaukos during the third quarter worth about $12,520,000. Harbor Capital Advisors Inc. purchased a new stake in Glaukos during the fourth quarter worth about $3,679,000. Finally, Victory Capital Management Inc. increased its stake in Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after purchasing an additional 64,031 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is owned by insiders.

Glaukos Stock Performance

Shares of GKOS opened at $104.14 on Monday. The stock has a 50 day moving average price of $145.94 and a 200 day moving average price of $138.90. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.89 billion, a price-to-earnings ratio of -36.29 and a beta of 0.99. Glaukos Co. has a 52-week low of $84.08 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Research analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

GKOS has been the topic of a number of recent research reports. BTIG Research boosted their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a research report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus boosted their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.